Daobin Zhou

6.4k total citations · 1 hit paper
312 papers, 3.4k citations indexed

About

Daobin Zhou is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Daobin Zhou has authored 312 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 112 papers in Pathology and Forensic Medicine, 96 papers in Oncology and 85 papers in Genetics. Recurrent topics in Daobin Zhou's work include Lymphoma Diagnosis and Treatment (95 papers), Chronic Lymphocytic Leukemia Research (50 papers) and Viral-associated cancers and disorders (42 papers). Daobin Zhou is often cited by papers focused on Lymphoma Diagnosis and Treatment (95 papers), Chronic Lymphocytic Leukemia Research (50 papers) and Viral-associated cancers and disorders (42 papers). Daobin Zhou collaborates with scholars based in China, United States and United Kingdom. Daobin Zhou's co-authors include Li J, Xinxin Cao, Minghui Duan, Lu Zhang, Wei Zhang, Hao Cai, Yan Zhang, Jian Sun, Ting Liu and Jun Feng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Daobin Zhou

277 papers receiving 3.3k citations

Hit Papers

The consensus from The Chinese Society of Hematology on i... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update
    2021 150 citations Daobin Zhou et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daobin Zhou China 28 1.2k 1.0k 961 890 762 312 3.4k
Michael Møller Denmark 34 1.6k 1.3× 1.3k 1.3× 440 0.5× 549 0.6× 1.0k 1.4× 161 4.2k
Mark Hertzberg Australia 28 1.5k 1.2× 1.7k 1.7× 1.1k 1.1× 273 0.3× 894 1.2× 166 3.5k
Wolfgang Knauf Germany 27 1.4k 1.1× 936 0.9× 1.0k 1.1× 159 0.2× 1.4k 1.8× 124 3.0k
Mihaela Onciu United States 26 732 0.6× 791 0.8× 2.0k 2.0× 290 0.3× 733 1.0× 54 3.8k
Alexander Claviez Germany 26 836 0.7× 751 0.7× 343 0.4× 462 0.5× 441 0.6× 80 2.1k
Stefan Hohaus Italy 39 1.0k 0.8× 1.4k 1.3× 1.5k 1.6× 256 0.3× 591 0.8× 167 4.2k
Eric Sariban Belgium 36 218 0.2× 518 0.5× 1.0k 1.1× 436 0.5× 1.4k 1.8× 107 3.5k
Dominique Plantaz France 39 456 0.4× 898 0.9× 567 0.6× 2.3k 2.6× 719 0.9× 173 4.7k
Bertrand Arnulf France 37 457 0.4× 1.6k 1.6× 2.3k 2.4× 177 0.2× 763 1.0× 167 4.8k
Bernhard Kremens Germany 36 457 0.4× 784 0.8× 1.6k 1.6× 935 1.1× 391 0.5× 83 3.6k

Countries citing papers authored by Daobin Zhou

Since Specialization
Citations

This map shows the geographic impact of Daobin Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daobin Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daobin Zhou more than expected).

Fields of papers citing papers by Daobin Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daobin Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daobin Zhou. The network helps show where Daobin Zhou may publish in the future.

Co-authorship network of co-authors of Daobin Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Daobin Zhou. A scholar is included among the top collaborators of Daobin Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daobin Zhou. Daobin Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Li, Junjie, Lin Peng, Daobin Zhou, et al.. (2024). Footprint family of China's coal-based synthetic natural gas industry. Energy. 312. 133560–133560. 3 indexed citations
4.
Su, Wei, et al.. (2024). Clinical characteristics, radiological features and outcomes in pulmonary involvement of cryoglobulinemia. Orphanet Journal of Rare Diseases. 19(1). 185–185.
5.
Wei, Chong, Song Xue, Hao Cai, et al.. (2024). Germline defects of familial hemophagocytic lymphohistiocytosis-related genes presenting as adult-onset peripheral T-cell lymphoma. Frontiers in Immunology. 15. 1365975–1365975. 2 indexed citations
6.
Chen, Hongyun, Wei Wang, Chong Wei, et al.. (2024). Lymphoma relapse 1 year or later after immunochemotherapy in DLBCL patients: clinical features and outcome. Clinical and Experimental Medicine. 24(1). 48–48. 2 indexed citations
7.
Zhang, Yan, Jingjing Ye, Hao Chen, Daobin Zhou, & Chunyan Ji. (2024). Efficacy and Safety of BTKis in Central Nervous System Lymphoma: A Systematic Review and Meta-Analysis. Cancers. 16(5). 860–860. 3 indexed citations
8.
Cai, Hao, et al.. (2024). BRAF Deletion in Adult Patients with Langerhans Cell Histiocytosis Correlates with Multisystem Disease and Poor Outcomes. Clinical Cancer Research. 31(1). 197–204. 1 indexed citations
9.
Chen, Chao, Zhe Zhuang, Hao Cai, et al.. (2024). Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA. Journal of Cellular and Molecular Medicine. 28(14). e18576–e18576. 5 indexed citations
10.
Wei, Chong, Shuqing Wang, Yan Zhang, et al.. (2023). The intrinsic defects of T cells impact the efficacy of CAR-T therapy in patients with diffuse large B-cell lymphoma. Blood Cancer Journal. 13(1). 186–186. 7 indexed citations
11.
Wei, Chong, et al.. (2023). Mutation profiling, tumour burden assessment, outcome prediction and disease monitoring by circulating tumour DNA in peripheral T‐cell lymphoma. British Journal of Haematology. 202(1). 86–95. 9 indexed citations
12.
Zhuang, Zhe, et al.. (2023). Three cases of late‐onset post CAR‐T therapy isolated CNS relapse in R/R large B‐cell lymphoma. European Journal Of Haematology. 112(2). 310–313. 2 indexed citations
13.
14.
An, Gang, Daobin Zhou, Shu Cheng, et al.. (2021). A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. Clinical Cancer Research. 27(20). 5492–5501. 25 indexed citations
15.
Zhang, Wei, Wei Wang, Xiao Han, et al.. (2021). Circulating tumor DNA by high‐throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas. International Journal of Laboratory Hematology. 43(5). 1041–1049. 9 indexed citations
16.
Qian, Long, et al.. (2019). Prognostic value of interim 18F-FDG PET/CT in T-cell lymphomas. Leukemia & lymphoma. 61(4). 927–933. 4 indexed citations
17.
Li, Jian, et al.. (2019). [Clinical role of Morphology in Diagnosing Bone Marrow Involvement of Diffuse Large B Bell Lymphoma].. PubMed. 27(2). 421–425. 1 indexed citations
18.
19.
Ji, Yali, Daobin Zhou, Yan Zhang, et al.. (2019). Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis. Hematology. 24(1). 392–398. 31 indexed citations
20.
Zhu, Tienan, Shujie Wang, Wei Zhang, et al.. (2015). [Clinical characteristics and outcome of patients with primary central nervous system lymphoma].. PubMed. 36(10). 849–52. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Møller Breakdown of academic impact, for papers by Mark Hertzberg Breakdown of academic impact, for papers by Wolfgang Knauf Breakdown of academic impact, for papers by Mihaela Onciu Breakdown of academic impact, for papers by Alexander Claviez Breakdown of academic impact, for papers by Stefan Hohaus Breakdown of academic impact, for papers by Eric Sariban Breakdown of academic impact, for papers by Dominique Plantaz Breakdown of academic impact, for papers by Bertrand Arnulf Breakdown of academic impact, for papers by Bernhard Kremens
Rankless by CCL
2026